All News
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Janet Pope Janetbirdope ( View Tweet)
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Anti-MAA Ab is not ‘baa’ humbug. In prevalent #RheumatoidArthritis, + MAA Ab was predictive of developing #RA #ILD. ? Novel biomarker. Needs validation but nice convincing data @RheumNow #ACR21 #ACRBest abst#1916 https://t.co/wuTPzSIsey
Janet Pope Janetbirdope ( View Tweet)
Another study linking long term GC and CV risk in RA!
Medicare data >65yo 130000+ pts
1-year incidence CV ⬆️ as follows:
📍Dose ≤5mg 1.4%
📍Dose 5-10mg 1.7%
📍Dose >10mg 1.9%
Not replicated in younger pts (Optum data)
#ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Aurelie Najm AurelieRheumo ( View Tweet)
Abst 1916
England & colleagues determined if anti-MAA Ab = predictor of incident RA-ILD
- Anti-MAA Ab significantly associated w/ incident RA-ILD
- Strongly associated w/ higher concentrations anti-MAA
- Antibody associations = antigen/isotype dependent
#ACR21 @RheumNow https://t.co/z1RspmxBvc https://t.co/hvUm4O6RmX
Akhil Sood MD AkhilSoodMD ( View Tweet)
DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid disease properly is the current best strategy for treating RA-ILD. Abstr#1918 #ACR21 @RheumNow #ACRBest https://t.co/FpUK6upyOi
Richard Conway RichardPAConway ( View Tweet)
Is there a relationship between the weather and RA disease activity?⛈️
#ACR21 Abs#1912
🌡️Temperature & humidity significantly affect pain, TJC & SJC
🌦️PGA was mostly influenced by humidity
Should we take the weather into account when assessing patients?
@RheumNow https://t.co/e3PewZWkLR
Mrinalini Dey DrMiniDey ( View Tweet)
RA ILD survival. The ‘smoking’ gun! RA ILD in VA pts mostly menand smokers - data showed disease activity of #RheumatoidArthritis & ⬆️HAQ both reduced survival independently #ACRBest #ACR21 abst#1918 @RheumNow https://t.co/8GD7rHV07t
Janet Pope Janetbirdope ( View Tweet)
Preventive Window of Opportunity in RA? Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract #0455 presented at the #ACR21 annual meeting.
https://t.co/bCN1k5hhUc https://t.co/gpEHk0XIRc
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we predict who will develop #RA-ILD?
Perhaps anti-MAA is the answer!
#ACR21 Abs#1916
👉🏼⬆️anti-MAA antibody assoc with incident ILD risk
👉🏼Associations are antigen &
isotype dependent
👉🏼Antibody measurement may be useful to risk stratify for RA-ILD
@RheumNow https://t.co/nC0OkuWtGU
Mrinalini Dey DrMiniDey ( View Tweet)
Once again #steroids are bad in #RheumatoidArthritis from 2 large admin databases in age >65 in Medicare data, not in younger pts -Optum data. Clear dose response #ACR21 #ACRBest @RheumNow abst#1915 https://t.co/XL93jty7C9
Janet Pope Janetbirdope ( View Tweet)
HCQ adherence (>90%) associated with 52% reduced cardiovascular mortality in RA and SLE. Seen for MI, stroke, not VTE. Abstr#1909 #ACR21 @RheumNow https://t.co/5UncmqZVNp
Richard Conway RichardPAConway ( View Tweet)
Claims data looked at 21,114 #RA & #SLE pts - 4.3% had CV Death. The risk of CVD was worse w/ HCQ nonadherence (HR 1.08; 0.91-1.31) and better w/ HCQ adherence (HR 0.51;0.42-.66) HCQ nonadherence shows higher CV mortality #ACR21 Abst# 1909 https://t.co/di1mBliMN6
Dr. John Cush RheumNow ( View Tweet)
Dementia is ⬆️in #RheumatoidArthritis says Elena Myasoedva but #RA has more DM &CV disease which ⬆️dementia. Need to separate vascular dementia from Alzheimer’s. When I trained we thought less dementia in RA -likely not true. More work is coming. 9T213 aging hub #ACR21 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept:
⭐️Seropositivity
⭐️no prior bMDARD use
⭐️low HAQ-DI
⭐️low BMI
Abst#1228 #ACR21 @Rheumnow https://t.co/NvJoSWScZs
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0120 presented at the #ACR21 annual meeting.
https://t.co/9yOM5rSARv https://t.co/Gq2YxbxkmM
Links:
Dr. John Cush RheumNow ( View Tweet)
Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept:
⭐️Seropositivity
⭐️no prior bMDARD use
⭐️low HAQ-DI
⭐️low BMI
Abst#1228 @ACR21 @Rheumnow https://t.co/LRd1HVbm5B
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abst 1661
Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA
- In women: Depression significantly associated w/ disability
- In men: HTN & Lung Disease significantly associated w/ disability
#ACR21 @RheumNow https://t.co/0qkn1TcvOi
Akhil Sood MD AkhilSoodMD ( View Tweet)
Hair Loss due to Methotrexate from RCTs in RA estimated at 6.9%.
It's an understandable source of concern for those taking the medication
#ACR21 https://t.co/GymV2RC7jT
Dr Irwin Lim _connectedcare ( View Tweet)
French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd
Dr. Rachel Tate uptoTate ( View Tweet)